Simon G E, Daniell W, Stockbridge H, Claypoole K, Rosenstock L
Group Health Cooperative of Puget Sound, Seattle, Washington.
Ann Intern Med. 1993 Jul 15;119(2):97-103. doi: 10.7326/0003-4819-119-2-199307150-00001.
To examine the role of immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity.
Case-control comparison.
Community allergy practice (cases), university-based clinics for musculoskeletal injuries (controls).
Forty-one patients with chemical sensitivity and 34 control patients with chronic musculoskeletal injuries.
Immunologic measures included autoantibody titers, lymphocyte surface markers, and interleukin-1 generation by monocytes. Psychological evaluation included standardized measures of anxiety, depression, and somatization.
Immunologic testing did not differentiate patients with chemical sensitivity from controls. The only difference noted (lower interleukin-1 generation among cases) appeared attributable to laboratory methods. Patients with chemical sensitivity reported greater prevalence of current anxiety or depressive disorder (44% versus 15%, P = 0.006). This difference, however, did not appear to precede the onset of chemical sensitivity, and 25% of chemically sensitive patients showed no significant current psychological disturbance. Cases reported significantly more "medically unexplained" physical symptoms before and after the onset of chemical sensitivity. When considering only symptoms that preceded chemical sensitivity, 25% of cases (and no controls) satisfied criteria for somatization disorder. Neuropsychological testing revealed no significant case-control differences.
Immunologic testing failed to confirm findings from earlier uncontrolled studies, militating against proposed immunologic mechanisms. The decreased memory and concentration frequently described in multiple chemical sensitivity were not confirmed by brief neuropsychological testing. Psychological symptoms, although not necessarily etiologic, are a central component of chemical sensitivity.
探讨免疫、心理和神经心理因素在多重化学敏感中的作用。
病例对照比较。
社区过敏诊所(病例组),大学附属肌肉骨骼损伤诊所(对照组)。
41例化学敏感患者和34例慢性肌肉骨骼损伤对照患者。
免疫指标包括自身抗体滴度、淋巴细胞表面标志物以及单核细胞产生白细胞介素-1的情况。心理评估包括焦虑、抑郁和躯体化的标准化测量。
免疫检测未能区分化学敏感患者和对照患者。唯一观察到的差异(病例组白细胞介素-1产生较低)似乎归因于实验室方法。化学敏感患者报告当前焦虑或抑郁障碍的患病率更高(44%对15%,P = 0.006)。然而,这种差异似乎并非在化学敏感发作之前出现,并且25%的化学敏感患者目前没有明显的心理障碍。病例组在化学敏感发作前后报告的“医学上无法解释的”身体症状明显更多。仅考虑化学敏感发作之前的症状时,25%的病例(对照组无)符合躯体化障碍的标准。神经心理测试显示病例组与对照组之间无显著差异。
免疫检测未能证实早期非对照研究的结果,不利于所提出的免疫机制。多重化学敏感中经常描述的记忆力和注意力下降未被简短的神经心理测试所证实。心理症状虽然不一定是病因,但却是化学敏感的核心组成部分。